{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:31:16Z","timestamp":1785256276163,"version":"3.55.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"UNITAID"},{"DOI":"10.13039\/100000060","name":"National Institutes of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR\/RR) tuberculosis (TB). However, such analyses are complicated when some patients die or become lost during post-treatment follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed data on 1991 patients who successfully completed a longer MDR\/RR-TB regimen containing bedaquiline and\/or delamanid between 2015 and 2018 in 16 countries. Using 5 approaches for handling post-treatment deaths, we estimated 6-month post-treatment TB recurrence risk overall and by HIV status. We used inverse-probability weighting to account for patients with missing follow-up and investigated the impact of potential bias from excluding these patients without applying inverse-probability weights.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The estimated TB recurrence risk was 7.4\/1000 (95% credible interval: 3.3\u201312.8) when deaths were handled as non-recurrences and 7.6\/1000 (3.3\u201313.0) when deaths were censored and inverse-probability weights were applied to account for the excluded deaths. The estimated risks of composite recurrence outcomes were 25.5 (15.3\u201338.1), 11.7 (6.4\u201318.2), and 8.6 (4.1\u201314.4) per 1000 for recurrence or (1) any death, (2) death with unknown or TB-related cause, or (3) TB-related death, respectively. Corresponding relative risks for HIV status varied in direction and magnitude. Exclusion of patients with missing follow-up without inverse-probability weighting had a small impact on estimates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The estimated 6-month TB recurrence risk was low, and the association with HIV status was inconclusive due to few recurrence events. Estimation of post-treatment recurrence will be enhanced by explicit assumptions about deaths and appropriate adjustment for missing follow-up data.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad589","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T20:53:18Z","timestamp":1695934398000},"page":"164-171","source":"Crossref","is-referenced-by-count":9,"title":["Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6754-4182","authenticated-orcid":false,"given":"Sara M","family":"Sauer","sequence":"first","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole D","family":"Mitnick","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzma","family":"Khan","sequence":"additional","affiliation":[{"name":"Interactive Research and Development (IRD) Global , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hewison","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Bastard","sequence":"additional","affiliation":[{"name":"Epicentre , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Holtzman","sequence":"additional","affiliation":[{"name":"Partners in Health , Maseru , Lesotho"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munira","family":"Khan","sequence":"additional","affiliation":[{"name":"IRD Global , Durban , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrivani","family":"Padayachee","sequence":"additional","affiliation":[{"name":"IRD Global , Durban , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Ahmed","sequence":"additional","affiliation":[{"name":"IRD Global , Karachi , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshan K","family":"Isani","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Directorate General Health Services , Sindh , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aga","family":"Krisnanda","sequence":"additional","affiliation":[{"name":"IRD Global , Jakarta , Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stalz Charles","family":"Vilbrun","sequence":"additional","affiliation":[{"name":"The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) , Port-au-Prince , Haiti"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagit","family":"Bektasov","sequence":"additional","affiliation":[{"name":"TB National TB Center , Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andargachew","family":"Kumsa","sequence":"additional","affiliation":[{"name":"Ministry of Health , Addis Ababa , Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisney","family":"Docteur","sequence":"additional","affiliation":[{"name":"Zanmi Lasante , Cange , Haiti"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tintaya","sequence":"additional","affiliation":[{"name":"Socios en Salud , Lima , Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McNicol","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Tbilisi , Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakob","family":"Atshemyan","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Yerevan , Armenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Voynilo","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Minsk , Belarus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thin Thin","family":"Thwe","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Yangon , Myanmar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwonjune","family":"Seung","sequence":"additional","affiliation":[{"name":"Partners in Health , Boston, Massachusetts , USA"},{"name":"Brigham and Women's Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rich","sequence":"additional","affiliation":[{"name":"Partners in Health , Boston, Massachusetts , USA"},{"name":"Brigham and Women's Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Huerga","sequence":"additional","affiliation":[{"name":"Epicentre , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palwasha","family":"Khan","sequence":"additional","affiliation":[{"name":"Interactive Research and Development (IRD) Global , Singapore , Singapore"},{"name":"Department of Clinical Research, London School of Hygiene & Tropical Medicine , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Franke","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"2024012801055331100_ciad589-B1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/sim.8471","article-title":"A causal framework for classical statistical estimands in failure\u2014time settings with competing events","volume":"39","author":"Young","year":"2020","journal-title":"Stat Med"},{"key":"2024012801055331100_ciad589-B2","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/aje\/kwad090","article-title":"Choosing questions before methods in dementia research with competing events and causal goals","volume":"192","author":"Rojas-Saunero","year":"2023","journal-title":"Am J Epidemiol"},{"key":"2024012801055331100_ciad589-B3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/EDE.0000000000001222","article-title":"The effect of prenatal treatments on offspring events in the presence of competing events: an application to a randomized trial of fertility therapies","volume":"31","author":"Chiu","year":"2020","journal-title":"Epidemiology"},{"key":"2024012801055331100_ciad589-B4","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/17407745221103853","article-title":"Rethinking intercurrent events in defining estimands for tuberculosis trials","volume":"19","author":"Pham","year":"2022","journal-title":"Clin Trials"},{"key":"2024012801055331100_ciad589-B5","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"2019"},{"key":"2024012801055331100_ciad589-B6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/cid\/cis1008","article-title":"Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence","volume":"56","author":"Franke","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2024012801055331100_ciad589-B7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1086\/655892","article-title":"Recurrence after treatment for pulmonary multidrug-resistant tuberculosis","volume":"51","author":"Becerra","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024012801055331100_ciad589-B8","doi-asserted-by":"crossref","first-page":"100268","DOI":"10.1016\/j.eclinm.2020.100268","article-title":"Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries","volume":"20","author":"Schw\u0153bel","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2024012801055331100_ciad589-B9","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1183\/09031936.06.00125705","article-title":"Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study","volume":"28","author":"Chiang","year":"2006","journal-title":"Eur Respir J"},{"key":"2024012801055331100_ciad589-B10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1164\/rccm.200801-132OC","article-title":"Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis","volume":"178","author":"Kim","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2024012801055331100_ciad589-B11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3201\/eid1204.041256","article-title":"Long-term follow-up for multidrug-resistant tuberculosis","volume":"12","author":"Shin","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2024012801055331100_ciad589-B12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/CMR.00061-05","article-title":"Molecular epidemiology of tuberculosis: current insights","volume":"19","author":"Mathema","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"2024012801055331100_ciad589-B13","first-page":"828","article-title":"Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk","volume":"11","author":"Panjabi","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024012801055331100_ciad589-B14","article-title":"Factors associated with mortality among patients on TB treatment in the southern region of Zimbabwe","volume":"2017","author":"Takarinda","year":"2017","journal-title":"Tuberc Res Treat"},{"key":"2024012801055331100_ciad589-B15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/ciw276","article-title":"Aggressive regimens reduce risk of recurrence after successful treatment of MDR-TB","volume":"63","author":"Khan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024012801055331100_ciad589-B16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.5588\/ijtld.11.0098","article-title":"Recurrence after successful treatment among patients with multidrug-resistant tuberculosis","volume":"15","author":"Lee","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024012801055331100_ciad589-B17","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.5588\/ijtld.11.0696","article-title":"Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002\u20132005","volume":"16","author":"Cavanaugh","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024012801055331100_ciad589-B18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1183\/09031936.00186310","article-title":"Shorter treatment duration for selected patients with multidrug-resistant tuberculosis","volume":"38","author":"Leung","year":"2011","journal-title":"Eur Respir J"},{"key":"2024012801055331100_ciad589-B19","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20189-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024012801055331100_ciad589-B20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias","volume":"15","author":"Herna\u0301n","year":"2004","journal-title":"Epidemiology"},{"key":"2024012801055331100_ciad589-B21","first-page":"99","volume-title":"Causal inference: what if","author":"Herna\u0301n","year":"2020"},{"key":"2024012801055331100_ciad589-B22","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1038\/s41598-018-23344-z","article-title":"Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis","volume":"8","author":"Samuels","year":"2018","journal-title":"Sci Rep"},{"key":"2024012801055331100_ciad589-B23","author":"World Health Organization","year":"2022"},{"key":"2024012801055331100_ciad589-B24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12879-023-08217-9","article-title":"Survival and predictors of mortality after completion of TB treatment among people living with HIV: a 5-year analytical cohort","volume":"23","author":"Lumu","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2024012801055331100_ciad589-B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-019-4378-4","article-title":"The endTB (Expand New Drugs for TB) observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens","volume":"19","author":"Khan","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2024012801055331100_ciad589-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2202\/1557-4679.1285","article-title":"A tutorial on methods to estimating clinically and policy-meaningful measures of treatment effects in prospective observational studies: a review","volume":"7","author":"Austin","year":"2011","journal-title":"Int J Biostat"},{"key":"2024012801055331100_ciad589-B27","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511802843","volume-title":"Bootstrap methods and their application","author":"Davison","year":"1997"},{"key":"2024012801055331100_ciad589-B28","author":"World Health Organization","year":"2022"},{"key":"2024012801055331100_ciad589-B29","first-page":"241","article-title":"Timing of relapse in short-course chemotherapy trials for tuberculosis","volume":"14","author":"Nunn","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024012801055331100_ciad589-B30","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/cid\/ciu186","article-title":"The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study","volume":"58","author":"Marx","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024012801055331100_ciad589-B31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ije\/dyp334","article-title":"Illustrating bias due to conditioning on a collider","volume":"39","author":"Cole","year":"2010","journal-title":"Int J Epidemiol"},{"key":"2024012801055331100_ciad589-B32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-soc-071913-043455","article-title":"Endogenous selection bias: the problem of conditioning on a collider variable","volume":"40","author":"Elwert","year":"2014","journal-title":"Annu Rev Sociol"},{"key":"2024012801055331100_ciad589-B33","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4102\/phcfm.v9i1.1406","article-title":"Undiagnosed tuberculosis in patients with HIV infection who present with severe anaemia at a district hospital","volume":"9","author":"Mntonintshi","year":"2017","journal-title":"Afr J Prim Health Care Fam Med"},{"key":"2024012801055331100_ciad589-B34","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/cid\/ciad051","article-title":"Analysis of dynamic efficacy endpoints of the Nix-TB trial","volume":"76","author":"Solans","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024012801055331100_ciad589-B35","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2024012801055331100_ciad589-B36","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"2024012801055331100_ciad589-B37","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N Engl J Med"},{"key":"2024012801055331100_ciad589-B38","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N Engl J Med"},{"key":"2024012801055331100_ciad589-B39","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad589\/53406215\/ciad589.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/1\/164\/56439022\/ciad589.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/1\/164\/56439022\/ciad589.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T01:06:26Z","timestamp":1706403986000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/1\/164\/7286370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,29]]},"published-print":{"date-parts":[[2024,1,25]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad589","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,15]]},"published":{"date-parts":[[2023,9,29]]}}}